Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

KemPharm nets $23.5mm in FOPO

11 Oct 2018

Executive Summary

KemPharm Inc. (pipeline of prodrugs for multiple CNS indications) netted $23.5mm through the public sale of 8.3mm shares at $3. The company plans to use the proceeds to fund its lead extended-release dexmethylphenidate prodrug candidates for attention deficit hyperactivity disorder (ADHD); an NDA submission for KP415 (anticipated Q1 2019); and the initiation of a pivotal trial for preclinical KP484 (expected to begin next year). Earlier this year, KemPharm's first prodrug--abuse-deterrent Apadaz (benzhydrocodone/acetaminophen) for short-term management of acute pain--was approved by the FDA.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By